Highland Capital Management (Texas)’s Ultragenyx Pharmaceutical RARE Stock Holding History

Highland Capital Management (Texas)’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$880K	Hold	13,855	–	–	0.05%	217
2019 Q1	$961K	Sell	13,855 -3,200	-19%	-$183K	0.06%	208
2018 Q4	$742K	Hold	17,055	–	–	0.06%	177
2018 Q3	$1.3M	Sell	17,055 -2,400	-12%	-$195K	0.07%	160
2018 Q2	$1.5M	Sell	19,455 -7,800	-29%	-$504K	0.08%	142
2018 Q1	$1.39M	Hold	27,255	–	–	0.07%	170
2017 Q4	$1.26M	Sell	27,255 -11,720	-30%	-$575K	0.06%	157
2017 Q3	$2.08M	Hold	38,975	–	–	0.09%	151
2017 Q2	$2.42M	Hold	38,975	–	–	0.1%	131
2017 Q1	$2.64M	Sell	38,975 -2,275	-6%	-$173K	0.13%	137
2016 Q4	$2.9M	Sell	41,250 -23,750	-37%	-$1.68M	0.14%	124
2016 Q3	$4.61M	Sell	65,000 -26,500	-29%	-$1.69M	0.14%	133
2016 Q2	$4.47M	Buy	+91,500	New	+$5.92M	0.18%	124

Other funds holding RARE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Highland Capital Management (Texas)'s RARE Position: Q2 2019 in Review

Highland Capital Management (Texas) held its Ultragenyx Pharmaceutical (RARE) position steady in Q2 2019 at 13,855 shares worth $880K. The position accounts for 0.05% of the portfolio, ranked #217.

Highland Capital Management (Texas) first reported a position in RARE in Q2 2016 and has held it in 13 quarters since. The position peaked at $4.61M in Q3 2016. 170 funds tracked by Wall St. Rank hold RARE as of Q2 2019.

Highland Capital Management (Texas) held 13,855 shares of Ultragenyx Pharmaceutical worth $880K as of Q2 2019.
Highland Capital Management (Texas) left its Ultragenyx Pharmaceutical share count unchanged in Q2 2019.
Ultragenyx Pharmaceutical made up 0.05% of Highland Capital Management (Texas)'s portfolio in Q2 2019, its #217 holding.
Highland Capital Management (Texas) first reported a position in Ultragenyx Pharmaceutical in Q2 2016 and has held it in 13 quarters since.
Highland Capital Management (Texas)'s Ultragenyx Pharmaceutical position peaked at $4.61M in Q3 2016.
170 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2019.

Based on Highland Capital Management (Texas)'s 13F filing for Q2 2019, filed 14 Aug 2019.